Sign In
Buy EVLO
$0.0001
+0 (+0%)
At Close: Jun 22, 2026
Evelo (EVLO) Posts Positive Data from Phase II Psoriasis Study
01:54pm, Tuesday, 28'th Sep 2021
Evelo Biosciences (EVLO) reports encouraging data from a phase II study evaluating EDP1815 for the treatment of mild and moderate psoriasis. Shares up in pre-market trading.
Evelo Biosciences Psoriasis Candidate Shows Benefit In Mid-Stage Study
07:40am, Monday, 27'th Sep 2021
Evelo Biosciences Inc (NASDAQ: EVLO) has announced data from its Phase 2 study of EDP1815 for mild and moderate psoriasis. A statistically significant reduction in the Psoriasis Area and Severity
–Clinically and statistically significant improvement in PASI-50 score achieved––EDP1815 safety and tolerability data comparable to placebo in study––EDP1815 advancing towards registration s
Implied Volatility Surging for Evelo Biosciences (EVLO) Stock Options
10:14am, Wednesday, 08'th Sep 2021
Investors need to pay close attention to Evelo Biosciences (EVLO) stock based on the movements in the options market lately.
Evelo Biosciences Appoints Iain McInnes, M.B.Ch.B, Ph.D, to Board of Directors
07:00am, Tuesday, 07'th Sep 2021
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announ
Evelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q2 2021 Results - Earnings Call Transcript
11:01pm, Saturday, 31'st Jul 2021
Evelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q2 2021 Results - Earnings Call Transcript
Evelo Biosciences Reports Second Quarter 2021 Financial Results and Business Highlights
07:00am, Thursday, 29'th Jul 2021
–EDP1815 Phase 2b data in psoriasis expected in 3Q 2021––Finalized design of Phase 2 clinical trial of EDP1815 in atopic dermatitis; start of trial anticipated in 3Q 2021––Strengthened leade
Evelo Biosciences to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021
07:00am, Thursday, 22'nd Jul 2021
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced tha
Evelo Biosciences Announces Grant of Inducement Award
04:01pm, Wednesday, 14'th Jul 2021
CAMBRIDGE, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced th
Evelo Biosciences Announces Grant of Inducement Award
04:01pm, Wednesday, 16'th Jun 2021
CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced th
Evelo Biosciences Announces Inducement Award Plan for Expanding Leadership Team
04:01pm, Thursday, 03'rd Jun 2021
CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced th
Evelo Biosciences: Monoclonal Microbes Offer Novel Inflammatory Treatment With A Favorable Risk-Reward Profile
07:17pm, Sunday, 16'th May 2021
Evelo Biosciences, Inc. is a clinical-stage biotechnology company developing novel oral biologics intended to act on cells in the small intestine for immunomodulatory effects. Evelo's pipeline consist
Evelo Biosciences, Inc (EVLO) CEO Simba Gill on Q1 2021 Results - Earnings Call Transcript
01:18am, Saturday, 01'st May 2021
Evelo Biosciences, Inc (EVLO) CEO Simba Gill on Q1 2021 Results - Earnings Call Transcript
Evelo Biosciences to Present at 20th Annual Needham Virtual Healthcare Conference
07:00am, Monday, 05'th Apr 2021
CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced th
-- Collaboration expected to accelerate access to Evelo's lead inflammation product candidate and COVID-19 therapeutic medicine EDP1815 - if approved by relevant health authorities - to people in sele
